Celgene – Health

Celgene taps Bristol-Myers salesforce to bolster key blood cancer launches

SAN FRANCISCO—After agreeing last year to swallow Celgene for a whopping $ 74 billion, Bristol-Myers Squibb trumpeted the potential of pairing its solid-tumor expertise with Celgene’s hematology expertise to create a leading cancer drugmaker. But the legacy BMS business had some hematology expertise of its own—and Celgene’s taking advantage, said Nadim Ahmed, the now-combined company’s… Read More »

Does Bristol-Myers Squibb’s new activist investor want to stall its Celgene buyout?

Analysts and investors have both expressed concerns over Bristol-Myers Squibb’s $ 74 billion Celgene deal agreement. And an activist may be joining that list. Known agitator Starboard Value has taken a stake in the New Jersey drugmaker, Bloomberg’s sources say, though the size of that stake and the hedge fund’s plans are still unclear. A… Read More »